دورية أكاديمية
أعرض في EDS

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype.

التفاصيل البيبلوغرافية
العنوان: Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype.
المؤلفون: Kobelyatskaya AA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Pudova EA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Katunina IV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Snezhkina AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Fedorova MS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Pavlov VS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Kotelnikova AO; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Nyushko KM; National Medical Research Radiological Center, Ministry of Health of the Russian Federation, 125284 Moscow, Russia., Alekseev BY; National Medical Research Radiological Center, Ministry of Health of the Russian Federation, 125284 Moscow, Russia., Krasnov GS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia., Kudryavtseva AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2023 May 25; Vol. 24 (11). Date of Electronic Publication: 2023 May 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/surgery, Male ; Humans ; Prostate ; Risk Factors ; Gene Expression Profiling ; Prostatectomy ; Transcriptome ; Oncogene Proteins, Fusion/genetics ; Transcriptional Regulator ERG/genetics ; Biomarkers, Tumor/genetics ; Chloride Channels/genetics ; Serine Endopeptidases/genetics
مستخلص: Molecular heterogeneity in prostate cancer (PCa) is one of the key reasons underlying the differing likelihoods of recurrence after surgical treatment in individual patients of the same clinical category. In this study, we performed RNA-Seq profiling of 58 localized PCa and 43 locally advanced PCa tissue samples obtained as a result of radical prostatectomy on a cohort of Russian patients. Based on bioinformatics analysis, we examined features of the transcriptome profiles within the high-risk group, including within the most commonly represented molecular subtype, TMPRSS2-ERG. The most significantly affected biological processes in the samples were also identified, so that they may be further studied in the search for new potential therapeutic targets for the categories of PCa under consideration. The highest predictive potential was found with the EEF1A1P5 , RPLP0P6 , ZNF483 , CIBAR1 , HECTD2 , OGN , and CLIC4 genes. We also reviewed the main transcriptome changes in the groups at intermediate risk of PCa-Gleason Score 7 (groups 2 and 3 according to the ISUP classification)-on the basis of which the LPL , MYC , and TWIST1 genes were identified as promising additional prognostic markers, the statistical significance of which was confirmed using qPCR validation.
References: Int J Biol Macromol. 2022 May 1;206:435-452. (PMID: 35202639)
Cell Signal. 2011 Mar;23(3):507-15. (PMID: 20813184)
Genes (Basel). 2017 Feb 16;8(2):. (PMID: 28212321)
PLoS One. 2011 Mar 07;6(3):e15612. (PMID: 21408220)
Mol Cancer. 2021 Jan 4;20(1):3. (PMID: 33397405)
Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404)
Life (Basel). 2021 Jun 21;11(6):. (PMID: 34205581)
Cell Death Dis. 2022 Jul 19;13(7):624. (PMID: 35853880)
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):. (PMID: 29311132)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
BMC Med Genomics. 2020 Sep 18;13(Suppl 8):129. (PMID: 32948204)
Int J Mol Sci. 2023 Jan 26;24(3):. (PMID: 36768739)
J Clin Lipidol. 2016 Jul-Aug;10(4):816-823. (PMID: 27578112)
PLoS One. 2015 Apr 21;10(4):e0122498. (PMID: 25897494)
Front Oncol. 2020 Dec 08;10:605154. (PMID: 33364199)
Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
Cancer Cell. 2010 Jul 13;18(1):11-22. (PMID: 20579941)
Exp Hematol Oncol. 2020 Nov 24;9(1):32. (PMID: 33292604)
Oncogene. 2014 May 22;33(21):2790-800. (PMID: 23770851)
Int J Mol Sci. 2020 Aug 15;21(16):. (PMID: 32824183)
Am J Surg Pathol. 2007 Jun;31(6):882-8. (PMID: 17527075)
Curr Oncol Rep. 2018 Jun 1;20(8):58. (PMID: 29858674)
Mol Cancer Res. 2013 Nov;11(11):1387-400. (PMID: 23982216)
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17087-92. (PMID: 21949389)
Eur Urol. 2016 Jul;70(1):93-105. (PMID: 26935559)
Bioinformatics. 2023 Jan 1;39(1):. (PMID: 36426870)
JAMA. 1998 Sep 16;280(11):969-74. (PMID: 9749478)
Oncogene. 2016 Jan 28;35(4):403-14. (PMID: 25915839)
Cell Metab. 2019 Sep 3;30(3):556-572.e5. (PMID: 31447321)
Mol Cancer Ther. 2011 Mar;10(3):427-36. (PMID: 21282354)
Nature. 2012 Jul 12;487(7406):239-43. (PMID: 22722839)
Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308)
Front Biosci (Landmark Ed). 2020 Jan 1;25(3):398-436. (PMID: 31585894)
Oncotarget. 2017 Mar 21;8(12):20380-20393. (PMID: 28099910)
Eur Urol. 2013 Oct;64(4):567-76. (PMID: 23759327)
Int J Cancer. 2020 Apr 1;146(7):2036-2046. (PMID: 31732966)
Eur Urol. 2015 Dec;68(6):1033-44. (PMID: 25913390)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)
Int J Mol Sci. 2022 Oct 02;23(19):. (PMID: 36232996)
J Clin Invest. 2013 Nov;123(11):4918-22. (PMID: 24135135)
PLoS One. 2014 Feb 05;9(2):e86824. (PMID: 24505269)
معلومات مُعتمدة: 18-75-10127 Russian Science Foundation
فهرسة مساهمة: Keywords: ISUP; RNA-Seq; TMPRSS2-ERG; gene expression; heterogeneity; molecular subtype; pathways; prostate cancer; risk groups; transcriptome
المشرفين على المادة: 0 (Oncogene Proteins, Fusion)
0 (Transcriptional Regulator ERG)
0 (Biomarkers, Tumor)
0 (ERG protein, human)
0 (CLIC4 protein, human)
0 (Chloride Channels)
EC 3.4.21.- (TMPRSS2 protein, human)
EC 3.4.21.- (Serine Endopeptidases)
0 (TMPRSS2-ERG fusion protein, human)
تواريخ الأحداث: Date Created: 20230610 Date Completed: 20230612 Latest Revision: 20230612
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10253008
DOI: 10.3390/ijms24119282
PMID: 37298233
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms24119282